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MicroRNA-3148 acts as molecular switch
promoting malignant transformation and
adipocytic differentiation of immortalized human
bone marrow stromal cells via direct targeting of
the SMAD2/TGFβ pathway
Radhakrishnan Vishnubalaji1, Ramesh Elango1, Muthurangan Manikandan2, Abdul-Aziz Siyal2, Dalia Ali3,
Ammar Al-Rikabi4, Dana Hamam5, Rimi Hamam6, Hicham Benabdelkamel7, Afshan Masood7, Ibrahim O. Alanazi8,
Assim A. Alfadda7, Musaad Alfayez2, Abdullah Aldahmash2, Moustapha Kassem2,3,9 and Nehad M. Alajez1
Abstract
MicroRNAs (miRs/miRNAs) play a key role in posttranscriptional regulation of gene expression and are implicated in a
number of physiological and pathological conditions, including cellular malignant transformation. In the current study,
we investigated the role of miR-3148 in regulating human stromal (mesenchymal) stem cell (hMSC) differentiation and
transformation. Stable expression of miR-3148 in telomerized hMSC (hMSC-miR-3148) led to significant increase in
in vitro adipocytic differentiation and suppression of osteoblastic differentiation. Concordantly, global gene expression
profiling revealed significant enrichment in cholesterol biosynthesis pathway, and pathways related to enhanced cell
movement and survival, whereas processes related to bone and connective tissue developments, cell death, apoptosis,
and necrosis were downregulated. Global proteomic analysis using 2D-DIGE followed by mass spectrometry (MS)
revealed significant changes in protein expression in hMSC-miR-3148 and enrichment in protein networks associated
with carcinogenesis. Functional studies revealed that hMSC-miR-3148 exhibited enhanced in vitro cell proliferation,
colony formation, migration, invasion, sphere formation, doxorubicin resistance, and increased active number of cells
in S and G2/M cell cycle phases and formed sarcoma-like tumors with adipocyte infiltration when implanted into
immunocompromised mice. SMAD2 was identified as bone fide gene target for miR-3148 using qRT-PCR, Western
blotting, and UTR-based reporter assay. In agreement with our data, SMAD2 expression was downregulated in 47% of
patients with soft tissue sarcoma. Bioinformatics analysis revealed that elevated miR-3148 expression correlates with
poor prognosis in several human cancer types, including sarcoma. Our study identified miR-3148 as factor regulating
hMSC differentiation and is involved in promoting malignant transformation of telomerized hMSC.
Introduction
MicroRNAs (miR/miRNA) are regulatory noncoding
double-stranded RNAs that exert posttranscriptional
regulation of gene expression under normal and patho-
logical conditions1. Global transcriptomic analysis of
miRNAs in cancer tissue compared with normal tissue
revealed differential expression of a number of miRNAs
which are either downregulated in cancer and thus exert a
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tumor suppressor role through direct targeting of onco-
genes or upregulated miRNAs, which act as oncomiRs
through inhibition of tumor suppressor genes2. Deregu-
lated miRNA expression is associated with large number
of human cancers, including breast, colon, gastric, lung,
and sarcomas3–8. MiRNAs have also been implicated in
regulating epithelial-to-mesenchymal transition, a process
leading to endowment of cancer cells with a mesenchymal
phenotype9.
MiRNAs have also been implicated in regulating stem
cell differentiation10. For instance, we have previously
shown the miR-320 family to promote adipocytic and to
inhibit osteoblastic differentiation of human bone marrow
stromal (mesenchymal) stem cells (hBMSCs) through
repression of RUNX2 expression11. Interestingly, we also
identified the miR-320 family to suppress colorectal can-
cer, through direct targeting of FOXM1, FOXQ1, and the
stem cell marker, SOX412, suggesting that miRNAs that
play a role in regulating stem cell functions, may be
associated with cancer development13.
In the current study, we investigated the biological
effects of miR-3148, identified from our previous micro-
RNA profiling during hMSC differentiation, on hMSC cell
differentiation into osteoblast and adipocytes. Functional
and molecular investigations revealed miR-3148 to pro-
mote adipogenesis and to suppress osteogenesis through
direct targeting of SMAD2/TGFβ pathway. In addition,
hMSC-miR-3148 exhibited enhanced in vitro cell pro-
liferation, colony formation, cell migration, cell invasion
and sphere formation, increased active S and G2/M cell
cycle phases, and formed sarcoma-like tumors when
implanted into immunocompromised mice, suggesting a
role for miR-3148 as regulator of stem cell differentiation
and transformation.
Results
MiR-3148 overexpression enhances adipocytic and
suppresses osteoblastic differentiation
Our previous global miRNA profiling identified miR-
3148 as significantly downregulated miRNA during
osteoblastic differentiation of human stromal (mesench-
ymal) stem cells (Supplementary Fig. 1). To unravel
potential role for miR-3148 during stem cell differentia-
tion, hMSC cells were transduced with a lentiviral vector
encoding for miR-3148 (hMSC-miR-3148) which exhib-
ited significant upregulation of miR-3148 expression
compared to hMSC-control cells (Supplementary Fig. 2).
Subsequently, hMSC-miR-3148 and hMSC-control cells
were subjected to adipocytic and osteoblastic differentia-
tion conditions. An enhanced adipocytic differentiation
was observed in hMSC-miR-3148 as evidenced by oil red
staining (Fig. 1a), Nile red quantification (Fig. 1b), and
quantitative reverse transcriptase-polymerase chain reac-
tion (qRT-PCR) for adipocyte protein 2 (AP2) and leptin
(LEP, Fig. 1c). On the other hand, hMSC-miR-3148
exhibited diminished ALP activity (Fig. 1d, e), decreased
in vitro mineralization (Fig. 1f, g) and decreased expres-
sion of osteoblastic gene markers: osteocalcin (OC),
osteonectin (ON), alkaline phosphatase (ALP), and Runt-
related transcription factor 2 (RUNX2, Fig. 1h).
miR-3148 regulates multiple genetic pathways in hMSC
To gain more insight into the molecular mechanisms by
which miR-3148 exert its effects during hMSC differ-
entiation, we performed global transcriptome analysis of
hMSC-miR-3148 compared to hMSC-control cells and
identified 1476 upregulated and 2370 downregulated
genes (2.0-fold change, p < 0.05, Supplementary Table 1)
in the hMSC-miR-3148. Hierarchical clustering showed
clear separate clustering of the hMSC-miR-3148 and
hMSC-control cells (Fig. 2a). The list of upregulated genes
were subsequently subjected to Ingenuity® Pathway
Analysis (IPA). Data presented in Fig. 2b depict the top
five enriched canonical pathways enriched in hMSC-miR-
3148 cells and included cholesterol biosynthesis. Analysis
for functional categories revealed significant enrichment
in several categories, including cellular movement, cel-
lular invasion, and cellular survival, while categories
related to cell death, apoptosis, and necrosis were sig-
nificantly underrepresented (Supplementary Fig. 3). The
cellular movement and cellular death and survival func-
tional categories are illustrated in Supplementary Fig. 3 as
well. IPA analysis on the downregulated genes in hMSC-
miR-3148 cells reveled significant downregulation in tis-
sue development functional categories (Supplementary
Fig. 3). Upstream regulator analysis of the differentially
expressed genes revealed significant enrichment in a
number of networks driven by Mitogen-Activated Protein
Kinase 1 (MAPK1), Interleukin 1 Receptor Antagonist,
Triggering Receptor Expressed On Myeloid Cells 1,
Activating Transcription Factor 4, Bruton Tyrosine
Kinase, TGF-Beta Activated Kinase 1 (MAP3K7) Binding
Protein 1 (TAB1), Amphiregulin (AREG), CCR4-NOT
Transcription Complex Subunit 7 (CNOT7), Vascular
Endothelial Growth Factor A, and TAL BHLH Tran-
scription Factor 1, Erythroid Differentiation Factor
(TAL1) (Supplementary Fig. 3).
In addition, we performed global proteomic analysis
using 2D-DIGE followed by protein identification by mass
spectrometry (MS). Proteomic analysis identified
2000 spots consistently mapped to all gels (Fig. 2c). Sixty
protein spots exhibited statistically significant change in
abundance in hMSC-miR-3148 compared to hMSC-
control cells (ANOVA-test p < 0.05; fold change > 1.5).
These spots were picked and further analyzed by MALDI-
TOF MS and identified 40 spots, which were matched
using the MASCOT peptide mass fingerprints (PMF) to
entries in the SWISS-PROT database with high
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confidence. Among the 40 spots, 21 spots were upregu-
lated and 19 spots were downregulated in hMSC-miR-
3148 compared to control cells (Fig. 2c, Supplementary
Fig. 4, and Supplementary Table 2). Pathway analysis of
the identified proteins revealed strong enrichment in
pathways associated with cancer development (Fig. 2d).
miR-3148 overexpression enhances colony formation, cell
migration and invasion
Transcriptomic and proteomic data revealed enrich-
ment in cancer-associated functional categories and sig-
naling pathways in the hMSC-miR-3148 model.
Therefore, we subsequently investigated the biological
effects of forced expression of miR-3148 on hMSC colony
formation, migration, and invasion. Data presented in
Fig. 3a revealed increased colony formation in hMSC-
miR-3148 compared to control cells, which were observed
in hMSC-miR-3148 as early as day 5, compared to control
cells. Scratch and xCELLigence real-time migration assays
revealed significant increase in cell motility and migration
of hMSC-miR-3148 (Fig. 3b, c). In addition, Boyden-
chamber transwell migration and invasion assay, revealed
enhanced migration (Fig. 3d) and invasion (Fig. 3e) of
hMSC-miR-3148.
miR-3148 overexpression enhances cell proliferation and
doxorubicin drug resistance
hMSC-miR-3148 cells exhibited increased cell pro-
liferation (Fig. 4a), formed a greater number of spheroids
when cultured under low-adherence cell culture
Fig. 1 hMSC-miR-3148 cells exhibited enhanced adipocytic and reduced osteoblastic differentiation of hMSC. a Representative Oil Red-O
staining on day 7 showing increased adipogenesis in hMSC-miR-3148 cells. Quantification of nile red staining (b) and adipocyte-specific gene marker
(AP2 and LEP) expression (c) in hMSC-miR-3148 vs hMSC-mcherry cells. d Representative ALP staining of osteoblast cells on day 10 in hMSC-miR-3148
vs hMSC-mcherry cells. Quantification of ALP activity (e) and alizarin red (ALZ, f) in hMSC-miR-3148 vs hMSC-mcherry cells. g Representative images of
alizarin red staining of mineralized matrix in hMSC-miR-3148 vs hMSC-mcherry cells performed on day 21. h Quantification of osteoblast specific gene
markers (OC, ON, ALP, and RUNX2) in hMSC-miR-3148 compared to hMSC-mcherry using qRT-PCR. Data are presented as mean ± S.E.M. from three
independent experiments, ***p < 0.0005.
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conditions (Fig. 4b). Notably, the spheroids formed by
hMSC-miR-3148 were more compact whereas control
cells-derived spheroids had irregular forms (Fig. 4b,
zoomed). Cell cycle analysis revealed significant decrease
in G0/G1 and significant increase in S and G2-M phases
of the cell cycle in hMSC-miR-3148 compared to controls
(Fig. 4c). Finally, hMSC-miR-3148 and control cells were
exposed to doxorubicin, a commonly used chemotherapy
in the treatment of human sarcomas14. hMSC-miR-3148
exhibited increased resistance to doxorubicin concentra-
tion ranging from 7.8 to 125 nM (Fig. 4d) and formation
of doxorubicin-resistant colonies was notable at 7.8 and
15.6 nM.
miR-3148 overexpression promotes sarcoma-like tumor
formation in vivo
Our in vitro data demonstrated enhanced cell pro-
liferation, colony formation, and migration in hMSC-miR-
3148 cells. Therefore, to examine the ability of
hMSC-miR-3148 to form tumors in vivo, we implanted
hMSC-miR-3148 and control cells loaded into Matrigel®
matrix, subcutaneously into immune deficient nude mice.
Concordant with the in vitro data, hMSC-miR-3148 cells
formed tumors, which were not detected in control cells
(Fig. 5a, b). We observed sustained high expression of
miR-3148 in the hMSC-miR-3148 xenografts (Fig. 5c).
Histological examination of the tumor tissue revealed a
Fig. 2 The hMSC-miR-3148 cell line exhibited multiple altered genetic pathways. a Hierarchical clustering of hMSC-miR-3148 compared to
hMSC-mcherry cells based on differentially expressed mRNA levels as determined by microarray analysis. Each column represents one replica and
each row represents an mRNA transcript. The expression level of each gene in a single sample is depicted according to the color scale. b Pie chart
illustrating the distribution of the top-5 canonical pathways based on Ingenuity Pathway Analysis (IPA) on the upregulated genes in the hMSC-miR-
3148 compared to hMSC-mcherry cells. The size of the chart segment corresponds to activation Z score. c Representative 2D-DIGE gel image. The
arrows indicate differentially regulated protein spots between hMSC-miR-3148 and hMSC-mcherry cells as determined by image analysis and
identified by MALDI-MS. The gray arrows indicate the upregulated and the red arrows indicate the downregulated proteins in hMSC-3148 cells.
d Schematic representation of the “Cancer, Organismal injury and abnormalities, cell death and survival” functional interaction network with the
highest score of 68 showing NFkB and IL6 as central nodes. Nodes in green and red correspond to down and upregulated proteins, respectively.
Noncolored nodes are proposed by IPA and suggest potential targets functionally coordinated with the differential proteins. Solid lines indicate
direct molecular interactions and dashed lines represent indirect relationships.
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Fig. 3 The hMSC-miR-3148 cells exhibited enhanced clonogenicity, migration and invasion potential. a Clonogenic (CFU) assay showing
enhanced colony forming capability of hMSC-miR-3148 compared to hMSC-mcherry control cells on day 5. Plates were stained using the Diff-Quik
staining set. Data are representative of two independent experiments for each condition and representative images of formed colonies (lower
panels) were taken at 1:32 dilution. b Measurement of hMSC-miR-3148 cell migration using in vitro scratch assay. Images were captures just after the
injury (0 h) and at 24 h. XCELLigence real-time cell analysis (RTCA) (c) and conventional (d) migration assay depicting enhanced migration of hMSC-
miR-3148 cells toward 1 and 10% serum condition compared to hMSC-mcherry control cells in a time-dependent manner. e Representative images
from conventional invasion assay demonstrating enhanced invasion capabilities hMSC-miR-3148 compared to hMSC-mcherry control cells.
Vishnubalaji et al. Cell Death Discovery            (2020) 6:79 Page 5 of 16
Official journal of the Cell Death Differentiation Association
Fig. 4 (See legend on next page.)
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sarcoma-like tumor tissue with numerous spindle and
pleomorphic cells and with mitotic figures (Fig. 5d). The
hMSC-miR-3148 tumors invaded skeletal muscles (Fig. 5e)
and surrounding nerves (Fig. 5f). Interestingly, tumor
tissue contained adipocytes suggesting a degree of adi-
pocyte differentiation (Fig. 5g).
miR-3148 regulates TGFβ signaling pathways through
direct targeting of SMAD2
In order to understand the molecular mechanism of
miR-3148, we compared the list of downregulated tran-
scripts in hMSC-miR-3148 cells to in silico predicted gene
targets using the Targetscan database15 and targetscan
algorithm16. We identified 527 downregulated transcripts
in hMSC-miR-3148 (Fig. 6a) and pathway analysis
revealed significant inhibition of a number of canonical
pathways related to osteogenesis, including TGFβ path-
way (Fig. 6b). Interestingly, we observed several members
of the SMAD family, which are TGFβ downstream
effectors, to be significantly downregulated: SMAD2: −4.1
FC, SMAD6: −5.2 FC, and SMAD9: −4.4 FC (Supple-
mentary Table 1). The expression of SMAD2 was subse-
quently validated using qRT-PCR and immunoblotting,
given its key role in mediating the TGFβ signaling path-
way. As seen in Fig. 6c, the expression and phosphoryla-
tion of SMAD2 were downregulated in hMSC-miR-3148.
(see figure on previous page)
Fig. 4 The hMSC-miR-3148 cells exhibited enhanced cell proliferation, sphere formation, and doxorubicin resistance. a Cell proliferation
measured using alamarblue assay of hMSC-miR-3148 compared to hMSC-mcherry cells on day 3 and day 4. Data are presented as mean percent
increase in cell proliferation ± S.E.M., n= 30 from two independent experiments, ***p < 0.0001. b Representative images depicting sphere formation
in hMSC-miR-3148 vs hMSC-mcherry cells on day 10. c Flow cytometry cell cycle analysis on hMSC-miR-3148 and hMSC-mcherry under normal
(upper panels) and serum starvation (lower panels) conditions. The proportion of cells in the G0-G1, S, and G2-M phases are indicated on each plot.
Quantitative analysis of cell cycle distribution in hMSC-miR-3148 and hMSC-mcherry is presented as bar diagram. Data are presented as mean ± S.E.
M., n= 3, **p < 0.005; ***p < 0.0005. d Representative fluorescence images of hMSC-miR-3148 and hMSC-mcherry control cells (±different
concentration (7.8–125 nM) doxorubicin). Cells were stained with acridine orange/ethidium bromide to detect apoptotic and necrotic cells. White
circles indicate resistant colonies.
Fig. 5 The hMSC-miR-3148 cells exhibited enhanced tumor formation in vivo. Both hMSC-miR-3148 and hMSC-mcherry control cells were
injected subcutaneously in nude mice. Representative images of tumor formed in each experimental group on day 28 is shown in (a). b Tumor size
(log scale) in each experimental group on day 14 and day 28 is presented as bar chart. Data are presented as mean tumor volume ± S.E.M., n= 4;
***p < 0.0005. c qRT-PCR quantification of hsa-miR-3148 expression in hMSC-miR-3148 Xenograft tissue compared to mcherry control cells. Data are
representative of three experiment and are presented as mean ± S.D., n= 3. d–g Representative histopathological examination of hMSC-miR-3148
xenograft tumors using haematoxylin and eosin stain. Arrows indicate mitotic figures (d), muscle invasion (e), nerve surrounding (f), and adipocyte
formation (g).
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In silico analysis revealed nine potential binding sites for
miR-3148 in SMAD2 3′ UTR (Fig. 6d). Luciferase-based
reporter assay corroborated our findings and validated
SMAD2 as bone fide target for miR-3148 (Fig. 6e).
To highlight the clinical relevance of our findings, we
examined the expression of SDMAD2 in the Memorial
Sloan Kettering Cancer Center and Broad Institute
(SKCC/BI) soft tissue sarcoma dataset, which revealed
significant downregulation of SMAD2 in 47% of sarcoma
patients in these cohorts (Fig. 6f). In addition, higher
expression of hsa-miR-3148 was associated with lower
overall survival in multiple human cancer types (breast,
cervical, esophageal, head and neck, ovarian, pancreatic,
and uterine) and sarcoma (Fig. 7).
Discussion
miRNAs orchestrate complex regulatory networks
across various biological systems. Each miRNA can reg-
ulate dozens of mRNA transcripts; and conversely, a
single mRNA transcript can be regulated by several
miRNAs. Interestingly, a single miRNA can exert multiple
effects in various biological system. Dysregulated miRNA
expression has been implicated in human diseases,
including diabetes, cardiovascular, kidney diseases and
cancer17–19. For instance, the let-7 family of miRNAs
regulates stem cell differentiation and predominantly
exert a tumor suppressor effects20,21. Similarly, we have
previously reported that miR-320 family plays a role in
hMSC osteoblastic and adipocytic differentiation and to
Fig. 6 miR-3148 regulates TGFβ signaling through direct targeting of SMAD2. a Venn diagram depicting the overlap between the
downregulated mRNA transcripts in hMSC-miR-3148 cells and in silico predicted gene targets for miR-3148 (based on TargetScan algorithm).
b Significantly altered canonical pathways revealed by IPA on the downregulated transcripts in hMSC-miR-3148 cells. c qRT-PCR and immunoblotting
showing the downregulation of SMAD2 and pSMAD2 proteins in hMSC-miR-3148 compared to control cells. d Illustration of the alignment of miR-
3148 and SMAD2 3′ UTR region using TargetScan algorithm indicated nine potential binding sites for miR-3148. e Luciferase-based reporter assay
illustrating the direct interaction between miR-3148 and SMAD2 3′UTR. Data are presented as mean ± S.E.M., n= 5 from two experiments. The two-
tailed t test was used to compare different treatment groups. f Oncoprint and bar chart depicting altered SMAD2 mRNA expression in soft tissue
sarcoma from the SKCC/BI soft tissue sarcoma dataset.
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suppress colorectal cancer proliferation and migra-
tion11,12. In the context of carcinogenesis, miRNA can be
classified as oncomiRs or as tumor suppressor miRNAs.
OncomiRs mediate their effects through downregulation
of tumor suppressor genes, leading to abnormal cell
functions and tumor development and progression22. For
example, the miR-21 oncomiR is overexpressed in many
human cancers, including, thyroid, breast, lung, CRC,
pancreas, liver, gastric, cervical, skin, glioblastoma, and
hematological malignancies23,24.
We observed that overexpression of miR-3148 in hMSC
led to enhanced cell proliferation, induced a transformed
cellular phenotype as well as formation of sarcoma-like
tumors when implanting the cells in vivo. We have also
Fig. 7 Higher expression of miR-3148 is unfavorable prognostic factor in multiple cancer types. Kaplan–Meier overall survival analysis for miR-
3148 expression in breast, cervical, esophageal, head and neck, ovarian, pancreatic, uterine cancer and sarcoma patients. Analyses were conducted
using Kaplan–Meier plotter available at http://kmplot.com/analysis/index.php?p=background. Survival curve comparison was performed using the
log-rank test.
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observed that miR-3148 targets TGFβ signaling pathway.
The role of TGFβ and BMPs is well documented during
bone formation, which signals through both canonical
SMAD-dependent and noncanonical SMAD-independent
signal transduction pathways25. In the context of tumor-
igenesis, TGFβ pathway exerts opposing role either as
promoter or as suppressor of tumor development and
progression26. Several studies highlighted an important
role for TGFβ in regulating cell proliferation and pro-
moting apoptosis in normal and transformed cells27. In
breast and colon cancers, TGFβ signaling exerts anti-
neoplastic effect during early stages, but eventually it
promotes carcinogenesis through mediating epithelial
mesenchymal transition (EMT)28. Interestingly, disrup-
tion of TGFβ signaling in the prostate of SV40 large T
antigen transgenic animals, did not affect the size of
neoplastic tumors, but instead it promoted tumor
metastasis29. Also, disruption of SMAD2 accelerates
malignant progression of intestinal tumors in apc
knockout mice, although the total number of intestinal
tumors in those animals was not affected30. Taken toge-
ther, the current studies suggest that disruption of TGFβ
accelerates tumorigenesis, while the loss of TGFβ signal-
ing is not sufficient to trigger malignant transformation.
Our data are in agreement with the aforementioned
reports where we observed miR-3148 to promote malig-
nant transformation of the telomerized-hMSC cells, while
forced expression of miR-3148 on its own has no sig-
nificant effects on the growth of primary skin derived
stromal cells (Supplementary Fig. 4). Telomerized-hMSC
model employed in current study has normal karyotype,
but exhibited deletion of the Ink4a/ARF locus and
therefore is more prone to malignant transformation31,
which provides a plausible explanation for the observed
data of differential effects of miR-3148 on telomerized-
hMSC compared to primary stromal cells. It also suggests
that inactivation of TGFβ via miR-3148/SMAD2 axis is a
“secondary hit” accelerating malignant transformation. In
Ewing’s sarcoma (ES), elevated expression of miR-20b was
shown to directly target TGFβ receptor II (TGFBR2)
leading to elevated MYC expression, hence inhibition of
miR-20b reduced ES cell grow, cell cycle progression, and
in vivo tumor formation, thus corroborating the impor-
tant role of loss of TGFβ signaling in promoting ES tumor
formation32. In addition to the SMAD2/TGFB pathway,
miR-3148-hMSC cells exhibited upregulation and down-
regulation of several onco- and tumor suppressor genes,
respectively. The role of other genes in regulating hMSC
differentiation and tumorigenesis in the context of miR-
3148 remains to be elucidated.
MiR-3148-hMSC cells exhibited enhanced resistance to
doxorubicin, a commonly used chemotherapy in the
treatment of human sarcomas. In order to provide
potential mechanism by which miR-3148 confers
doxorubicin resistance, gene expression data from
GSE3362 was retrieved and the upregulated and down-
regulated genes in doxorubicin-resistant sarcoma were
identified and were crossed with the list of differentially
expressed genes in miR-3148-hMSC cells. Our data
revealed common upregulated (ACADVL, RAG1,
CYP51A1, PLAT, ITGA5, LOX, MAP4, MMP1, SCG5,
STC1, THBS1, ZNF91, TNFRSF25, DDIT3, SLC16A3,
SYNGR2, XRCC3, SEMA3A, POLR3G, TFPI2, KLF2,
REEP2, TOR4A, STEAP3, APBB1IP, and SLC25A19) and
common downregulated (CYP1B1, GJA1, IGFBP2,
GSTM3, CD70, AMPH, LIF, MSX1, OAS2, THBS4,
TPD52L1, BHLHE40, RUNX3, FGL1, DHRS3, FGR,
SLC7A8, CD24, CELSR1, TCAF1, DACT1, PHF10, FEZ1,
and C15orf48), Supplementary Fig. 6. For instance,
RUNX3 was previously shown to inhibit hepatocellular
carcinoma growth in vitro and in vivo in combination
with Adriamycin33. Concordantly, reduced expression of
AMPH1 was previously shown to be associated with
breast cancer metastatic, advanced stage, poor clinical
outcome, and Paclitaxel plus 5-fluorouracil/ epirubicin/
cyclophosphamide treatment resistance34. The role of
other genes in mediating doxorubicin residence in miR-
3148-hMSC warrants further investigation.
A number of studies highlighted various mechanism
leading to malignant transformation of hMSCs. For
instance, methylation of HIC ZBTB Transcriptional
Repressor 1 (HIC1) and Ras Association Domain Family
Member 1 (RassF1A) tumor suppressor genes was suffi-
cient to transform bone marrow MSCs into malignant
cells endowed with tumor‐initiating capabilities35. Alter-
natively, a number of genetic modification were utilized to
transform hMSCs into malignant sarcoma cells. The
combination of hTERT/H-RAS and hTERT/H-RAS/
SV40-LT has been demonstrated to induce pleomorphic
sarcoma cells36–38. Transformed hMSCs using combina-
tion of hTERT and H-RAS retained their adipocytic and
chondrogenic, while osteoblastic differentiation was
completely lost38. Our current study corroborates these
findings since miR-3148 overexpressing hMSC-TERT
cells exhibited enhanced adipogenesis and suppressed
osteogenesis, suggesting the loss of osteogenic differ-
entiation is a common feature during malignant trans-
formation of hMSC. Interestingly, we found positive
correlation between elevated expression of miR-3148 and
poor prognosis in several human cancer types, including
sarcomas thus highlighting miR-3148 as a possible prog-
nostic biomarker in various human cancers. In support of
this hypothesis, recent data reported higher expression of
miR-3148 in 3D-spheroids formed using the HCT116
human CRC model39. miR-3148-overexpressing HCT116
cells exhibited enhanced tumor formation in vivo, were
resistant to hypoxic conditions and exhibited higher
sensitivity to MAPKK and ERK inhibitors39.
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In addition to its possible role in carcinogenesis, a role
for miR-3148 in the context of other pathological condi-
tions has been reported. miR-3148 levels were inversely
correlated with Toll-like receptor 7 (TLR7) transcript
levels in peripheral blood monocytes obtained from sys-
temic lupus erythematosus (SLE) patients40. Interestingly,
the G allele of rs3853839 in the 3’ UTR of TLR7 has
diminished binding capability to miR-3148, which was
associated with elevated TLR7 transcript expression and
increased risk for SLE, thus implicating miR-3148-TLR7
circuit in SLE pathogenesis40. Elevated levels of miR-3148
were also associated with congestive heart failure (CHF)
in a cohort of 44 CHF patients and 15 healthy subjects41.
In addition, downregulation of miR-3148 was observed in
chronic pulmonary hypertension42.
In conclusion, our data provide novel insight on the role
of miR-3148-SMAD2-TGFβ axis during malignant
transformation of hMSCs into sarcoma-like cancer and
suggest therapeutic approaches targeting miR-3148/
SMAD2/TGFβ pathway as plausible therapeutic strategy.
Materials and methods
Cell culture and lentiviral transduction
We employed a well-characterized telomerase-trans-
duced adult bone marrow hMSC cell line (hMSC-TERT)
that expresses all known markers and possess similar
differentiation potential to primary hMSCs in vitro and
in vivo43,44. For simplicity, this line is referred to as hMSC
throughout the paper. Those cells were cultured in Dul-
becco’s modified Eagle’s medium (DMEM) supplemented
with 4500 mg/l D-glucose, 4 mM L-glutamine, 110mg/l
sodium pyruvate, 10% fetal bovine serum (FBS), 1%
penicillin-streptomycin, and nonessential amino acids as
previously described43.
Lentiviral particles encoding for hsa-miR-3148 (LP-
HmiR0781-MR03-0200-S) and control particles were
purchased from Genecopoeia (Genecopoeia Inc., Rock-
ville, MD, USA). Transduction was performed as pre-
viously described12. Briefly, hMSCs were treated with
20 μl of crude lentiviral particles in 500 μl of transduction
medium (DMEM+ 5% heat-inactivated serum and 1%
Pen-Strep (Invitrogen)) with polybrene (8 μg/ml; Sigma,
St. Louis, MO, USA). After 24 h, media was removed and
cells were selected with puromycin (1 μg/ml, Sigma, St.
Louis, MO, USA) for 1 week until stably transduced cells
were generated. Transduction efficiency was confirmed
using qRT-PCR for miR-3148 expression compared to
mcherry-transduced cells.
Gene expression profiling by microarray
Gene expression profiling was performed as previously
described45. In brief, total RNA was extracted using the
total tissue RNA purification kit from Norgen-Biotek
Corp. (Thorold, ON, Canada) and quantified in
NanoDrop 2000 spectrophotometer (Thermo Scientific,
Wilmington, DE, USA). One-hundred fifty ng of total
RNA was labeled and then hybridized to the Agilent
Human SurePrint G3 Human GE 8 × 60k microarray chip
and subsequently data were analyzed using GeneSpring
13.0 software (Agilent Technologies, Palo Alto, CA, USA).
Single experiment pathway analysis tool was used with
twofold expression cutoff (p < 0.05). Benjamini–Hochberg
False Discovery Rate (FDR) method was used for multiple
testing corrections.
Ingenuity pathway and network analysis
Pathway analyses were conducted using Ingenuity path-
way (Ingenuity Systems, http://www.ingenuity.com)46. Dif-
ferentially expressed genes exhibiting ≥ 2 ≤ and p value <
0.05 were subjected to core analysis using the human
database. Enriched networks categories were algor-
ithmically generated based on their connectivity and ranked
according to the Z score.
qRT-PCR
The expression levels of the indicated mRNA transcipts
were validated using SYBR Green-based qRT-PCR using the
applied biosystems ViiA™ 7 real-time PCR system (Ther-
moFisher Scientific). Primers used in current study are listed
in Table 1. Differential expression was calculated using the
2ΔCT method and data were plotted as bar diagram.
Protein extraction for mass spectrometry
Proteins were extracted from three biological replicate
(~2 × 106 cells) from the hMSC-miR-3148 or hMSC-
Table 1 List of SYBR green primers used in current study.
No Name Sequence
1 AP2 F 5′ TGGTTGATTTTCCATCCCAT
R 5′ GCCAGGAATTTGACGAAGTC
2 LEP F 5′ CAGCGGTTGCAAGGCCCAAGA
R 5′ GGCCAAAGCCACAAGAATCCGC
3 OC F 5′ GGCAGCGAGGTAGTGAAGAG
R 5′ CTCACACACCTCCCTCCTG
4 ON F 5′ GAGGAAACCGAAGAGGAGG
R 5′ GGGGTGTTGTTCTCATCCAG
5 ALP F 5′ GGAACTCCTGACCCTTGACC
R 5′ TCCTGTTCAGCTCGTACTGC
6 RUNX2 F 5′ GTAGATGGACCTCGGGAACC
R 5′ GAGGCGGTCAGAGAACAAAC
7 β-actin F 5′ AGCCATGTACGTTGCTA
R 5′ AGTCCGCCTAGAAGCA
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mcherry cells directly in lysis buffer (0.5 mL, pH 8.8,
30 mM Tris buffer containing 7M urea, 2M thiourea, 2%
Chaps, 1× protease inhibitor mix). The suspension was
shaken for 1 h at room temperature and then sonicated
(Microsonicator, Qsonica Sonicators, USA; 30% pulse,
two intervals of 1 min each, separated by a 1min gap in
ice). Fifty mM dithiothreitol was then added and the
protein extracts were centrifuged (20,000 × g, 1 h, 4 °C).
The pellet was then removed and the solubilized proteins
in the supernatant were precipitated using a 2D clean-up
kit according to the manufacturer’s protocol (GE
Healthcare, USA).
Protein labeling with cyanine dyes
The protein pellets were solubilized in labeling buffer
(7M Urea, 2 M Thiourea, 30 mM Tris-HCl, 4% CHAPS,
pH 8.5). Insoluble materials were pelleted by centrifuga-
tion (12,000 × g, room temperature (RT), 5 min), protein
concentrations were determined in triplicate using the
2D-Quant kit (GE Healthcare, USA), and the pH of the
samples was adjusted to 8.5 using NaOH (100mM).
Proteins were labeled (400 pmol of CyDye™ DIGE Fluor
dyes, GE Healthcare, UK) in 1 μl of DMF and then mixed
with sample containing 50 μg of protein. Samples were
incubated on ice for 30min in the dark. The labeling
reaction was terminated by adding 1 μl of 10 mM lysine.
Each sample was covalently labeled with a fluorophore,
either Cy3 or Cy5. A mixture of equal amounts of protein
isolated from each and every sample in the experiment
was labeled with Cy2 and used as internal standard.
Two dimensional gel electrophoresis (2D-DIGE)
First dimension analytical gel electrophoresis was per-
formed as follows. Six Immobiline Dry Strips (24 cm, pH
3–11; GE Healthcare, Sweden) were passively re-hydrated
(30 V, 12 h). This was followed by isoelectric focusing
using an Ettan IPGphor IEF unit (GE Healthcare, Swe-
den). Focusing was performed at 20 °C, at 50 μA per strip,
according to the following step and hold sequence: i.e., (1)
500 V for 1 h, (2) 1000 V for 1 h, (3) 8000 V for 3 h, (4)
45,000 V for 1 h. After the first dimension, the strips were
equilibrated and separated on 12.5% (SDS-PAGE) gels
using an Ettan Dalt Six device (GE Healthcare, Sweden).
The gels were scanned with a Typhoon 9400 scanner (GE
Healthcare) using appropriate wavelengths and filters for
Cy2, Cy3, and Cy5 dyes. Total protein (1 mg) was
obtained from a pool of equal protein amounts of each
sample. This was denatured in lysis buffer, then mixed in
a rehydration buffer. Gels were then stained by Colloidal
Coomassie Blue staining (Supplementary Fig. 4).
Protein Identification by MALDI-TOF MS
The spots from Coomassie-stained gels were excised
manually, washed, and digested according to a previously
published protocol47. The mixture of tryptic peptides
(1 µL), derived from each protein, was spotted onto a
MALDI target (384 anchorchip MTP 800 µm Anchorchip;
BrukerDaltonik, Germany) together with 0.8 μL of matrix
(10 mg α-cyano-4-hydroxycinnamic acid (CHCA) in 1 μL
of 30% CH3CN and 0.1% aqueous CF3COOH) and then
left to dry (RT) before MS analysis. Spectra were acquired
using a MALDI-TOF MS (UltraFlexTrem, Bruker Dal-
tonics) in the positive mode with target voltage of 25 kV
and pulsed ion extraction voltage of 20 kV. The reflector
voltage was set to 21 kV and detector voltage to 17 kV.
PMF were calibrated against a standard (Peptide Cali-
bration Standard II, Bruker Daltonics). The PMF were
processed using the Flex AnalysisTM software (version
2.4, Bruker Daltonics). The MS data were interpreted
using BioTools v3.2 (Bruker Daltonics), together with the
MASCOT search algorithm (version 2.0.04 updated 09/
05/2017; Matrix Science Ltd., UK). MASCOT search
parameters were set as follows: fixed propionamide
modification of cysteine, oxidation of methionine as
variable modification, one missed cleavage site (such as in
the case of incomplete trypsin hydrolysis), and a mass
tolerance of 100 ppm. Identified proteins were accepted as
correct if they showed a MASCOT score > 56 and p <
0.05. Not all spots of interest could be identified because
some proteins were low in abundance and did not yield a
sufficiently intense mass of fingerprints; other spots were
mixtures of multiple proteins.
Image acquisition and statistical analysis
DIGE images were analyzed using Progenesis Same
Spots v3.3 software (Nonlinear Dynamics Ltd., UK). First,
images were aligned. Prominent spots were used to
manually assign; 45 vectors to digitized images within
each gel and then the automatic vector tool was used to
add additional vectors (390 total vectors), which were
manually revised and edited for correction if necessary.
These vectors were used to warp and align gel images with
a reference image of one internal standard across and
within each gel. Gel groups were established according to
the experimental design and spot normalized volume
(NV) was used to select statistically significant spots. The
software calculated the NV of each spot on each gel from
Cy3 (or Cy5) to Cy2 spot volume ratio. The software
performs log transformation of the spot volumes to gen-
erate normally distributed data. Log normalized volume
(LNV) was used to quantify differential expression.
Independent direct comparisons were made between
hMSC-miR-3148 and hMSC-mcherry cells and fold dif-
ferences and p values were calculated using one-way
ANOVA. All spots were pre-filtered and manually
checked before applying the statistical criteria (ANOVA-
test, p ≤ 0.05 and fold ≥ 1.5). Normalized spot volumes,
instead of spot intensities, were used in statistical
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processing. Only those spots that fulfilled the above-
mentioned statistical criteria were submitted for MS
analysis.
Protein network Pathway analysis
Pathway analysis was carried out by importing the
quantitative data into the IPA software (Ingenuity® Sys-
tems, http://www.ingenuity.com). This software aids in
determining the functions and pathways that are most
strongly associated with the protein list by overlaying the
experimental expression data on networks constructed
from published interactions.
Cell differentiation
Adipocytic and Osteoblastic differentiation were per-
formed as previously described43,48. In brief, cells were
cultured in basal medium till 70–80% confluence.
Osteogenic induction medium consisting of DMEM
containing 10% FBS, 1% P/S, 50 μg/mL L-ascorbic acid
(Wako Chemicals GmbH, Neuss, Germany), 10 mM
β-glycerophosphate (Sigma), and 10 nM calcitriol[(1α,25-
dihydroxy vitamin D3) (sigma)], 10 nM dexamethasone
(Sigma) was added. Adipogenic-induction mixture con-
taining 10% FBS, 10% Horse Serum (Sigma), 1% P/S,
100 nM dexamethasone, 0.45 mM isobutyl methyl xan-
thine [Sigma], 3 μg/mL insulin (Sigma), and 1 μM Rosi-
glitazone [(BRL49653) (Novo Nordisk, Bagsvaerd,
Denmark)] were added to adipogenic cultures. Both
induction media were replaced every 3 days.
Cytochemical assays
Cytochemical analyses were performed to confirm the
adipocyte and osteoblast lineage differentiation of hMSC as
previously described48. In brief, all cytochemical images
were taken using Carl Zeiss—Axio observer1 equipped with
digital camera (Axiocam MRc5, Göttingen, Germany).
Oil red-O staining for adipocytes
Cells were washed in PBS, fixed in 4% formaldehyde and
stained for 1 h at RT with filtered Oil red-O staining
solution (prepared by dissolving 0.5 g Oil red-O powder in
60% isopropanol). Cells were rinsed with water and then
photographed.
Nile red staining of oil filled droplets
Cells were grown in flat bottom 96-well black micro-
plates (Corning, NY, USA) and after washing, cells were
stained with nile red (5 μg/ml in PBS), followed by an
incubation for 10min at RT then washed twice with PBS.
Fluorescent signal was measured using SpectraMax/M5
fluorescence spectrophotometer plate reader (Molecular
Devices Co., Sunnyvale, CA, USA) using bottom well-scan
mode where nine readings were taken per well using
Excitation (485 nm) and Emission (572 nm) wavelength.
Alkaline phosphatase activity (ALP) staining and
quantification
We used the BioVision ALP activity colorimetric assay
kit (BioVision, Inc., Milpitas, CA, USA) to quantify ALP
activity. Cells were cultured in 6-well (for image analysis)
and 96-well plates under normal or osteogenic induction
conditions, on day 10 cells were washed with PBS and
were fixed in 3.7% formaldehyde+ 90% ethanol for 30 s at
RT. Subsequently, fixative was removed and 50 μl of
pNPP (p-nitrophenyl phosphate) solution was added and
incubated for 1 h in the dark at RT. Reaction was subse-
quently stopped by adding 20 μl stop solution then mea-
sured and photographed.
Alizarin Red S (ALZ) staining for mineralized matrix
formation
Cells were differentiated and stained on day 21. Twelve
well plates were washed with PBS and then fixed with 4%
paraformaldehyde for 15min at RT. Subsequently, cells
were washed in distilled water and stained with 2% Ali-
zarin Red S Staining Kit (ScienceCell, Research Labora-
tories) for 30 min at RT. Subsequently, the dye was
washed off with water then plates were photographed and
staining intensity was quantified.
Cell proliferation
The proliferation of hMSC-mcherry and hMSC-miR-
3148 cells was determined using alamarBlue assay as
previously described12. Briefly, 5000 cells were cultured in
a 96-well plate and cell proliferation was measured at the
indicated time points by adding 1:10 volume of the ala-
marBlue assay reagent and measuring fluorescence exci-
tation and emission wavelengths of 530 nm and 590 nm,
respectively).
Clonogenic assay
The colony forming ability was determined using clo-
nogenic assay as previously described12. Briefly, cells were
seeded in 12-well plates at different dilution (1:2–1:32).
Primary seeding density was 0.015 × 106 cells per well, and
incubated at 37 °C under 5% CO2 for 5 days. The plates
were then washed and stained with Diff-Quik stain set
(Siemens Healthcare Diagnostics), and subsequently
scanned colonies were observed under microscope.
Sphere formation assay
Multicellular tumor spheroids were produced in 60mm
low cell binding dishes (Nunc; ThermoFisher Scientific).
The hMSC-mcherry and hMSC-miR-3148 cells were
trypsinized from monolayers and transferred to the
dishes. The formation of tumor spheroids was performed
with 10,000 cells. On day 10, established spheroids were
analyzed and stained with acridine orange and ethidium
bromide.
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Cell cycle analysis by flow cytometry
Cell cycle analysis was performed as described earlier48,
briefly, cell pellets were washed in PBS and re-suspended
and stained in 500 μl PBS supplemented 100 μg/ml
RNAse A (Sigma, St. Louis, MO, USA) and 50 μg/ml of
Propidium Iodine and were analyzed by Navious flow
cytometer (Beckman Coulter, Miami, Florida, USA).
Staining was detected in the fluorescence channel (FL3)
and the data were analyzed using Kaluza software
(Beckman Coulter).
Scratch assay
For the assessment of cell migration, confluent cells
were maintained in standard medium and subsequently,
scratches were made using a plastic micropipette tip
(yellow tip; 20–200 μL). After washing, the medium was
replaced with fresh medium. Photographs of the wounded
area were taken immediately (0 h) and after 20 h using
phase-contrast microscopy.
Migration assay
Conventional and real-time measurement of cell
migration was carried out as described earlier12. In brief,
real time migration was executed using the xCELLigence
RTCA DP device (ACEA Biosciences, San Diego, CA).
Cells were starved for 24 h in 1% serum media, followed
by seeding 0.08 × 106 cells per well in 16-well microelec-
tronic sensor plate, two chamber transwell plates (CIM-
plate insert; ACEA Bioscience) containing the respective
serum conditions. Media containing 10% serum (chemo-
attractant) and 1% serum (negative control) were added to
the bottom wells. Similarly, for conventional migration,
the BD transwell migration system with 8μ pore size was
utilized. Inserts were placed in a 24-well plate, and 0.1 ×
106 cells in 1% serum were added to the top of the
chamber, and 10% serum added to the bottom of the
chamber. Eighteen hours later, inserts were fixed and
stained with SIEMENNS DIFF-QUICK stain set (Siemens
Healthcare Diagnostics).
Invasion assay
For invasion assay, we followed similar set up as in the
migration assay, in addition, extracellular matrix (ECM)
material—Matrigel was added on top of the transwell
membrane. Matrigel was thawed on ice and then 50 µl
was added to a 24-well transwell insert and was allowed to
solidify at 37 °C for 30 min to form a thin gel layer. Cells
were added on top of the Matrigel coating to simulate
invasion through the ECM.
Acridine orange and ethidium bromide staining (AO/EtBr)
AO/EtBr stainig was performed as previously descri-
bed;12 briefly, after doxorubicin drug treatment, both
hMSC-mcherry and hMSC-miR-3148 cells were stained
with dual fluorescent staining solution (1 μl) containing
100 μg/ml AO and 100 μg/ml EtBr (Sigma, St. Louis,
MO). Cells were washed twice with PBS and were gently
mixed with AO/EtBr (1:100) dye solution for 1 min. The
cells were then observed and photographed using a Nikon
Eclipse Ti fluorescence microscope. Cells cultured with-
out drug were considered as experiment control.
Luciferase reporter assay
Luciferase reporter assay was performed as previously
described12. Briefly, HEK293 cells were transfected with
complexes containing control or SMAD2 UTR plasmids
(100 ng), pre-miR control or pre-miR-3148 (50 nM)
mixed with lipofectamine 2000 (Part No: 52758; Invitro-
gen) in Opti-MEM (11058-021; Gibco, Carlsbad, CA,
USA). Luciferase activity was measured using the Secrete-
Pair™ Dual Luminescence assay kit (Secrete Gaussia
luciferase (GLU) and Secreted Alkaline Phosphatase
(SEAP); GeneCopeia Inc., USA) according to the manu-
facturer’s instructions luminescence was measured in
SpectraMax M5 (Molecular Devices; USA) luminescence
reader. The ratio of luminescence intensities of the GLU
over SEAP was calculated and normalized to controls.
Western blot analysis
SMAD2 and pSMAD2 protein expression was analyzed
by western blot as previously described48. Briefly, cell
lysate samples containing 30 µg of total protein were
separated and blotted using the Bio-Rad V3 Western
Workflow system according to the manufacturer’s
recommendation. Immunoblotting was performed using
Phospho-SMAD2 (Ser465/Ser467), cat# E8F3R Rabbit
mAb and anti-SMAD2, cat# D43B4 XP® Rabbit mAb, cell
signaling technology (Danvers, MA, USA). The primary
antibody was incubated overnight at 4 °C. Horseradish
peroxidase (HRP)-conjugated goat anti-rabbit was used as
the secondary antibody, whereas HRP-conjugated anti-
GAPDH (glyceraldehyde-3-phosphate dehydrogenase)
antibody (1:1000; Invitrogen) was used as a loading con-
trol. Chemiluminescent detection was performed using
WesternSure Chemiluminescent Substrate (LI-COR,
Lincoln, NE, USA).
In vivo xenograft assay in nude mice
In vivo tumor formation was carried out as previously
described49. Briefly, 6–8-week-old male immunodeficient
nude mice were utilized in the xenograft experiments.
Two million of hMSC-mcherry or hMSC-miR-3148 cells
were mixed (1:1) with Matrigel (BD Biosciences, San Jose,
CA, USA) and subcutaneously injected into both flanks of
nude mice. Tumor mass was measured on day 14 and 28
using a caliper, and tumor volume was calculated using
the formula: volume= (tumor length × width × width)/2
as described before50. At the end of the experiment,
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tumors were excised, fixed in 10% buffered formalin,
embedded in paraffin, and sectioned on a microtome.
Sections were then stained with hematoxylin/eosin and
anti-Pan Keratin (AE1/AE3/PCK26).
Ethical approval
Animal experiments received the appropriate institu-
tional ethical from the Animal Care Committees of King
Saud University (No. KSU-SE-18-2).
Immunohistochemistry
Immunohistochemical (IHC) staining protocol was
performed as previously described49. Four-micron-thick
sections were stained using hematoxylin and eosin (H &
E) using the IHC staining protocol with fully automated
IHC/ISH staining instrument (Ventana Medical system
Inc, Tucson, Arizona, USA).
SMAD2 expression in soft tissue sarcoma and miR-3148
pan-cancer survival analysis
The expression of SMAD2 was interrogated in the
(SKCC/BI soft tissue sarcoma dataset as described
before51. Prognostic value of miR-3148 in breast, cervical,
esophageal, head and neck, ovarian, pancreatic, and
uterine cancer and sarcoma was investigated as described
before52.
Statistical analysis
Statistical analyses and graph generation were per-
formed using Microsoft Excel 2010 and GraphPad Prism
6.0 software (GraphPad, San Diego, CA, USA). p values
were calculated using the two-tailed t test. p value < 0.05
was considered significant.
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